The National Institutes of Health…
The National Institutes of Health is continuing its mission to [...]
Eli Lilly has pulled the plug on a…
Eli Lilly has pulled the plug on a phase 2b [...]
The FDA’s rejection of Telix…
The FDA’s rejection of Telix Pharmaceuticals’ imaging agent has triggered [...]
Merck & Co. is choosing to…
Merck & Co. is choosing to license one of Evaxion’s [...]
While the average earnout…
While the average earnout potential per biopharma deal has declined [...]
Sparrow Pharmaceuticals is looking…
Sparrow Pharmaceuticals is looking to send its potential diabetes treatment [...]
Harmony Biosciences’ $60 million…
Harmony Biosciences’ $60 million bet on a once-failed Fragile X [...]
Sanofi is bestowing $625 million…
Sanofi is bestowing $625 million on its investment arm Sanofi [...]
Rome Therapeutics is on the ropes,…
Rome Therapeutics is on the ropes, with the Boston-based preclinical [...]
The New York Stock Exchange helped…
The New York Stock Exchange helped ring in this year’s [...]